Latest Car T News

Prescient Therapeutics cut its net loss by 4.4% to $7 million in FY26 while expanding its PTX-100 Phase 2a trial across three continents and securing key regulatory designations in Europe and the US.

Coast Entertainment (ASX:CEH) posted a $6.1 million net profit in FY26, driven by strong theme park attendance and record revenues, while securing a major land development approval that boosts asset value by over $50 million.

Auckland Airport posted a 3% revenue increase and a stable underlying profit of NZD 309 million in FY26, driven by robust passenger growth and a $1 billion infrastructure push, while cautioning on near-term fuel price volatility and geopolitical risks.

Turners Automotive Group delivered record FY26 results with a 14% dividend rise, underpinned by strong growth in Auto Retail, Finance, and Insurance despite geopolitical headwinds.

Coast Entertainment updates valuations for its Dreamworld and SkyPoint assets, revealing a $52 million immediate uplift for Dreamworld following expanded land use approvals and a $14.7 million increase for SkyPoint.

AdAlta’s lead CAR-T therapy EW-001 continues to demonstrate encouraging survival and response rates in its mesothelioma study, with all patients alive at the latest follow-up and stronger outcomes at higher doses supporting plans for an Australian Phase 1 trial.

CAR Group Limited reported a 14% increase in net profit after tax to AUD 332.4 million for FY26, driven by strong revenue growth and AI innovation across its global vehicle marketplaces.

AdAlta’s lead CAR-T therapy EW-001 has achieved a rare clinical milestone with one mesothelioma patient remaining cancer-free two years after treatment, and a second reaching one-year survival, underscoring the therapy’s potential durability in a notoriously difficult cancer.

Monadelphous has secured a $200 million contract from BHP to deliver key infrastructure works at the Nelson Point Port Facility in Port Hedland, signalling a significant boost for its engineering construction division.

Mesoblast delivered US$115 million in Ryoncil® revenue in its first full year post-FDA approval, while expanding clinical trials into adult indications and acquiring cutting-edge CAR technology to boost its cell therapy pipeline.

AdAlta has completed a key US$1 million milestone payment securing rights to its lead CAR-T therapy EW-001 outside Greater China, progressed Australian manufacturing with first runs expected late 2026, and is preparing for a critical pre-IND meeting with the US FDA.

Arovella Therapeutics secured ethics approval and manufactured its first clinical batch of ALA-101, targeting blood cancers, while progressing its solid tumour program and refining autoimmune strategies. The company ended the quarter with $14.4 million in cash, supporting imminent clinical milestones.